COMP <GO>
A vs MRK // EV/EBITDA & P/E VALUATION
Agilent Technologies Inc. (NYSE) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: A 3
— MRK 11
▲ EV/EBITDA & P/E VALUATION LEADER: MRK
LAST: $174.87 (-3.47%) • MKT CAP: $51.07B
valuation
28.4x
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
valuation
15.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (A VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | A | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 52.40% | 74.80% | -22.40 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 15.30% | 20.70% | -5.40 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 28.4x | 15.3x | +13.10 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 2.26% | 3.42% | -1.16 | MRK | /fcf-yield <GO> |
| Operating Margin | 21.30% | 34.30% | -13.00 | MRK | /operating-margins <GO> |
| Net Profit Margin | 18.80% | 28.10% | -9.30 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 6.70% | 1.30% | +5.40 | A | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.55% | 2.26% | -1.71 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.50 | 5.19 | +1.31 | A | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | A | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.60% | 6.60% | 0.00 | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.9 | 56.9 | -1.95 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.91 | 0.92 | -0.01 | MRK | /macro-sensitivity <GO> |
| Forward P/E Multiple | 36.5x | 18.4x | +18.10 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $51.07B | $361.02B | -$309.95B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | A REV | MRK REV | A GROSS % | MRK GROSS % | A FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $6.95B | $65.01B | 52.4% | 74.8% | $1.15B | $12.36B |
| FY 2024 | $6.51B | $64.17B | 54.3% | 76.3% | $1.37B | $18.10B |
| FY 2023 | $6.83B | $60.12B | 44.0% | 44.0% | $1.46B | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
A // BETA 0.91
MRK // BETA 0.92